Ardelyx, Inc. (ARDX)

NASDAQ: ARDX · IEX Real-Time Price · USD
1.18
+0.03 (2.61%)
At close: Sep 28, 2022 4:00 PM
1.20
+0.02 (1.69%)
After-hours: Sep 28, 2022 7:42 PM EDT
2.61%
Market Cap 182.47M
Revenue (ttm) 5.20M
Net Income (ttm) -134.83M
Shares Out 154.64M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,768,139
Open 1.15
Previous Close 1.15
Day's Range 1.14 - 1.22
52-Week Range 0.49 - 1.92
Beta 1.67
Analysts Buy
Price Target 4.59 (+289.0%)
Earnings Date Nov 10, 2022

About ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX0... [Read more...]

Industry Biotechnology
IPO Date Jun 19, 2014
CEO Michael Raab
Employees 86
Stock Exchange NASDAQ
Ticker Symbol ARDX
Full Company Profile

Financial Performance

In 2021, Ardelyx's revenue was $10.10 million, an increase of 33.36% compared to the previous year's $7.57 million. Losses were -$158.17 million, 67.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 288.98% from the latest price.

Price Target
$4.59
(288.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass. , Sept. 6, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines...

3 weeks ago - PRNewsWire

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 307.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass.

1 month ago - PRNewsWire

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines ...

1 month ago - PRNewsWire

Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

— Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass.

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ardelyx, Inc.

Wilmington, Delaware--(Newsfile Corp. - July 22, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Ardelyx, Inc. (NASDAQ: ARDX) on behalf of stockholder...

2 months ago - Newsfile Corp

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass. , July 1, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines ...

2 months ago - PRNewsWire

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration partner WAL...

2 months ago - PRNewsWire

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines...

3 months ago - PRNewsWire

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

WALTHAM, Mass. , June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines ...

3 months ago - PRNewsWire

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Three poster presentations continue to highlight the safety and efficacy of IBSRELA based on data from two Phase 3 trials in adults with irritable bowel syndrome with constipation (IBS-C) WALTHAM, Mass....

4 months ago - PRNewsWire

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adult...

WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines t...

4 months ago - PRNewsWire

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass. , May 5, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo...

4 months ago - PRNewsWire

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

— Conference Call scheduled for 4:30 PM Eastern Time WALTHAM, Mass. , April 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...

5 months ago - PRNewsWire

Why Ardelyx Shares Are Rising

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company's second level of appeal of ...

5 months ago - Benzinga

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ: ARDX) second level of appeal of the Complete Response Lett...

5 months ago - Benzinga

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

- Ardelyx welcomes the opportunity for the company, patients, and practicing nephrologists to speak to clinically meaningful results in treating hyperphosphatemia - WALTHAM, Mass. , April 25, 2022 /PRNe...

5 months ago - PRNewsWire

Kyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal Disorders

Ardelyx Inc (NASDAQ: ARDX) has amended its license agreement, initially executed in 2017, granting Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for cardiorenal diseases,...

5 months ago - Benzinga

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

WALTHAM, Mass. , April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicine...

5 months ago - PRNewsWire

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foun...

Four posters support the important role that XPHOZAH, with its novel phosphate blocking mechanism, could potentially play in the treatment of hyperphosphatemia XPHOZAH alone or in combination with binde...

5 months ago - PRNewsWire

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

IBSRELA ® (tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in Adults First Novel Mechanism Therapy to Treat IBS-C in a Decade Product Now Available WALTHAM, Mass....

5 months ago - PRNewsWire

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference

WALTHAM, Mass., March 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines ...

6 months ago - PRNewsWire

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stand...

6 months ago - Benzinga

Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research